DOC

Business profile & competitive position

Healthpeak Properties, Inc. (ticker: DOC) is an S&P 500, self-administered UPREIT classified in the Real Estate sector, REIT – Healthcare Facilities industry. Through its operating subsidiary, Healthpeak OP, it owns, operates and develops U.S. healthcare real estate: outpatient medical buildings and hospitals, lab / life-science buildings, and senior housing. As of December 31, 2025, the portfolio held interests in 689 properties.

What the returns say about competitive durability is mixed. Net margin is 8.6% and return on equity is 3.3% — neither figure points to a high-return, margin-rich franchise in the classic wide-moat sense. Yet the lease structure is built for stability: outpatient medical buildings were approximately 79% on or adjacent to hospital campuses, approximately 96% affiliated with hospital systems and approximately 72% triple-net leased by leased square feet; the segment also includes nine triple-net leased hospitals. Labs were approximately 89% triple-net leased by leased square feet. Triple-net leases push many operating costs to tenants, so the modest margin says more about accounting rents, capital intensity and capital structure than about pricing power. For Healthpeak, tenant credit quality, lease duration and location adjacency to hospital systems look like the real foundations of resilience, not a high-margin operating moat.

Financial posture

Healthpeak’s current market capitalization is $14.9 billion, with a P/E ratio of 61.7. At first glance that multiple looks steep next to a net margin of 8.6% and an ROE of 3.3%. Closer inspection matters: REITs are often valued on funds from operations (FFO) or net asset value rather than GAAP earnings, because depreciation and gains/losses on property sales can make the headline P/E noisy. Still, the numbers confirm that GAAP earnings are thin relative to price, so the stock is pricing in expectations well above current net income.

Beta is 0.99, implying nearly market-level systematic risk. That is consistent with a diversified, investment-grade healthcare property owner: not deeply defensive in the way a low-beta consumer staple might be, but also not a high-beta growth stock. The combination of a large market cap, near-1.0 beta and low ROE suggests a capital-intensive, yield-and-appreciation vehicle rather than a high-return operating company.

Strategic priorities & outlook

Healthpeak’s most recent 10-K sets four operational priorities.

• Grow and manage high-quality outpatient medical, lab and senior housing real estate for long-term risk-adjusted returns and dividend growth.
• Keep an investment-grade balance sheet with ample liquidity, primarily long-term fixed-rate debt and staggered maturities to limit interest-rate and refinancing risk.
• Drive internal growth by working with tenants on space and capital needs, replacing tenants at favorable terms, extending or modifying leases before expiration, and delivering strong property management to encourage renewals, expansions and relocations.
• Complete the proposed Janus Living IPO in the first half of 2026 by contributing its 34-community senior housing portfolio, retaining a substantial majority ownership interest and acting as external manager.

Portfolio economics behind those priorities are telling. For 2025, segment Adjusted NOI was $795,843 thousand from outpatient medical, $567,358 thousand from lab, and $176,741 thousand from senior housing. The lab footprint is highly concentrated: 59% of lab square feet in San Francisco, 22% in Boston and 17% in San Diego. In January 2026, Healthpeak acquired the remaining 46.5% interest in its SWF SH JV, taking full ownership of 19 senior housing properties. Translation: management is not just collecting rents; it is reshaping the portfolio — monetizing senior housing through an IPO while tightening its grip on select operating assets.

Macro & geopolitical exposure

As a healthcare facilities REIT, Healthpeak sits at the intersection of real estate capital markets and healthcare policy. The most relevant macro exposures include:

• Interest rates and credit spreads. REITs are rate-sensitive because they use leverage and trade relative to fixed-income yields. Healthpeak explicitly targets long-term fixed-rate debt with staggered maturities to manage refinancing risk.
• Healthcare reimbursement and regulation. Tenant demand for outpatient buildings, hospitals and senior housing ultimately depends on Medicare, Medicaid and commercial insurance payment rules, plus broader health-policy shifts.
• Biotech and R&D funding. Lab properties in San Francisco, Boston and San Diego are tied to life-science tenants whose expansion plans are sensitive to venture-capital flows and pharmaceutical R&D budgets.
• Construction costs, labor and insurance. New development, tenant improvements and rebuilding costs move with commodity prices, wages and property-insurance premiums.
• Demographics. Longer-term senior-housing and outpatient demand tracks aging populations, even if short-term occupancy and rent growth fluctuate.

None of these are company-specific shocks, but they are the unavoidable background risks for the REIT – Healthcare Facilities industry.

Recent developments

August 2026 brought a cluster of institutional and options-related headlines:

• On August 21, 2026, defenseworld.net reported that Advisors Capital Management LLC bought 75,700 shares of Healthpeak Properties, Inc.
• On the same day, defenseworld.net noted BlackRock Inc. holds a $1.52 billion stake in the company — roughly 10.2% of the current $14.9 billion market cap.
• On August 14, 2026, zacks.com listed Healthpeak among “2 Finance Stocks That Could Beat Earnings.”
• On August 10, 2026, zacks.com asked whether the options market was predicting a spike in the stock.

None of these headlines change the underlying rental economics, but they do flag that large asset managers are accumulating shares and that derivatives markets were pricing in elevated earnings-related volatility heading into the August 2026 report.

Earnings behavior & post-earnings drift

Over the last eight reported quarters, Healthpeak has beaten earnings estimates 4 times — a 50% beat rate — with an average earnings surprise of 18.2%. The average 5-day price move after earnings across those quarters is +2.24%, classified as an upward drift. A surface reading would say “beats produce gains,” but the quarter-by-quarter detail shows the signal is far less reliable than that.

The four most recent reports make the point:

• 2026-08-04: EPS of $0.08 versus an estimate of $0.02815, a 184.2% surprise beat. The next session gained 0.79%, but the five-day move was -5.13%.
• 2026-05-05: EPS of $0.28 versus an estimate of $0.05276, a 430.7% surprise beat. The stock surged 18.11% the next day and 19.81% over five days.
• 2026-02-02: EPS of $0.16 versus an estimate of $0.45, a -64.4% miss. The stock fell 2.78% the next day and drifted -0.47% over five days.
• 2025-10-23: EPS of -$0.17 versus an estimate of $0.06, a -383.3% miss. The stock actually rose 1.19% the next day, then slid -5.23% over the next five sessions.

The takeaway is clear: even on beat quarters, the post-earnings drift has not reliably continued in the direction of the surprise. The May 2026 beat produced a massive pop-and-hold, while the August 2026 beat — still a substantial 184.2% surprise — was essentially sold. The October 2025 miss even produced a positive one-day reaction before the five-day drift turned negative. With the next report scheduled for October 22, 2026 after the close and the consensus EPS estimate at $0.05625, traders should treat the average +2.24% drift as a statistical summary, not a playbook for the next release. At a price of $21.595, an RSI of 54.7 and a 50-day EMA of $21.03, the chart is essentially flat relative to its short-term trend — giving neither a bullish nor a bearish technical edge on its own.

For a deeper dive into how professional analysts are interpreting Healthpeak’s valuation, balance-sheet strategy and upcoming October 2026 earnings setup, take a look at the full institutional verdict rather than relying on headline numbers alone.